144 related articles for article (PubMed ID: 3080892)
1. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.
Kletzky OA; Borenstein R; Mileikowsky GN
Am J Obstet Gynecol; 1986 Feb; 154(2):431-5. PubMed ID: 3080892
[TBL] [Abstract][Full Text] [Related]
2. Variability and selectivity of anterior pituitary response to dopamine agonists throughout the normal menstrual cycle.
Kletzky OA; Shangold GA
Am J Obstet Gynecol; 1986 Feb; 154(2):362-7. PubMed ID: 3080890
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts SW; Quik RF
J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Lancet; 1981 Sep; 2(8248):659-61. PubMed ID: 6116045
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.
Blackwell RE; Bradley EL; Kline LB; Duvall ER; Vitek JJ; DeVane GW; Chang RJ
Fertil Steril; 1983 Jun; 39(6):744-8. PubMed ID: 6343127
[TBL] [Abstract][Full Text] [Related]
6. Control of hyperprolactinemia with pergolide.
Mattox JH; Bernstein J; Buckman MT
Int J Fertil; 1986; 30(4):39-43. PubMed ID: 2890594
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonists in hyperprolactinemia.
Mattox JH
Fertil Steril; 1985 Oct; 44(4):555-7. PubMed ID: 4054333
[No Abstract] [Full Text] [Related]
8. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.
Berezin M; Avidan D; Baron E
Isr J Med Sci; 1991 Jul; 27(7):375-9. PubMed ID: 2071373
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
10. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
Bergh T; Nillius SJ; Wide L
Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
[TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Horowitz BL; Hamilton DJ; Sommers CJ; Bryan RN; Boyd AE
AJNR Am J Neuroradiol; 1983; 4(3):415-7. PubMed ID: 6410759
[TBL] [Abstract][Full Text] [Related]
12. Vaginal bromocriptine administration in patients with hyperprolactinemia.
Carranza-Lira S; González-Sánchez JL; Martínez-Chequer JC
Int J Gynaecol Obstet; 1999 Apr; 65(1):77-8. PubMed ID: 10390107
[No Abstract] [Full Text] [Related]
13. Hyperprolactinemia with prolonged amenorrhea reversed with bromocriptine in a menopausal woman.
Goldman M; Steinberger A; Ganti S
Am J Obstet Gynecol; 1988 Jan; 158(1):117-8. PubMed ID: 3122579
[TBL] [Abstract][Full Text] [Related]
14. Pergolide, a potent long-acting dopamine-receptor agonist.
Lemberger L; Crabtree R; Callaghan JT
Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
[No Abstract] [Full Text] [Related]
16. Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment.
Strauch G; Valcke JC; Mahoudeau JA; Bricaire H
J Clin Endocrinol Metab; 1977 Mar; 44(3):588-90. PubMed ID: 576425
[TBL] [Abstract][Full Text] [Related]
17. Hyperprolactinemic primary amenorrhea: case report with successful prolactin-lowering treatment and review of the literature.
Farrari C; Telloli P; Rampini P; Caldara R
Gynecol Obstet Invest; 1980; 11(6):317-26. PubMed ID: 6785158
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Ferrari C; Barbieri C; Caldara R; Mucci M; Codecasa F; Paracchi A; Romano C; Boghen M; Dubini A
J Clin Endocrinol Metab; 1986 Oct; 63(4):941-5. PubMed ID: 3745407
[TBL] [Abstract][Full Text] [Related]
19. Effect of bromo-ergocryptine on serum hPRL, hLH, hFSH, and estradiol 17-beta in women with galactorrhea-amenorrhea.
Dickey RP; Stone SC
Obstet Gynecol; 1976 Jul; 48(1):84-9. PubMed ID: 934580
[TBL] [Abstract][Full Text] [Related]
20. Failure of bromocriptine to suppress prolactin in majeptil-induced hyperprolactinemia.
Yarkoni S; Spitz IM; Ben-David M; Polishuk WZ
Acta Eur Fertil; 1978 Dec; 9(4):185-8. PubMed ID: 573042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
